← Research index · Disorder page · Source YAML

Cross-provider research synthesis

Aflatoxin Related HCC

MONDO:0007256 Curated 2026-07-04T00:00:00Z 9 harmonized findings

falcon · 30 citations openscientist · 48 citations

Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

The TP53 codon 249 R249S mutation (a G->T transversion, AGG->AGT, p.Arg249Ser) is the molecular hallmark/fingerprint of aflatoxin B1 exposure in hepatocarcinogenesis.

UNANIMOUS INTEGRATED

pathophysiologygenetic_factor

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	the hallmark hotspot is TP53 codon 249 AGG→AGT (R249S), regarded as a molecular fingerprint of aflatoxin exposure Falcon names the codon 249 AGG→AGT (R249S) hotspot as the molecular fingerprint of aflatoxin exposure. DOI:10.1016/j.canlet.2009.02.057, DOI:10.3390/jox15040096
openscientist	CONCORDANT	97%	The TP53 R249S mutation (AGG→AGT, p.Arg249Ser) is the most specific molecular biomarker of AFB1 exposure in hepatocarcinogenesis, functioning as both a diagnostic indicator and a mechanistic driver of disease. OpenScientist calls R249S the most specific molecular biomarker of AFB1 exposure and adds that it is both diagnostic marker and mechanistic driver. PMID:20538734, PMID:29749584

Hepatic cytochrome P450 bioactivation of AFB1 to the reactive 8,9-exo-epoxide, which forms AFB1-N7-guanine (and FAPY) DNA adducts driving G->T transversions, is the initiating molecular event of aflatoxin hepatocarcinogenesis.

UNANIMOUS INTEGRATED

pathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	AFB1 is bioactivated in liver to the 8,9-exo-epoxide, generating AFB1-N7-Gua and FAPY adducts that drive G>T transversions Falcon describes the CYP bioactivation to the 8,9-exo-epoxide and the resulting N7-guanine/FAPY adducts producing G>T transversions. DOI:10.3390/jox15040096, DOI:10.3390/toxins18020090
openscientist	CONCORDANT	90%	The metabolic activation of AFB1 by hepatic cytochrome P450 enzymes is the critical initiating step in aflatoxin-induced carcinogenesis. OpenScientist agrees this is the initiating step and adds enzyme-level detail (CYP1A2 primary at physiological concentrations, CYP3A4 at higher). PMID:8261428

Chronic hepatitis B virus (HBV) infection and aflatoxin exposure interact in a more-than-multiplicative (supra-multiplicative) manner, producing far higher HCC risk than either factor alone.

UNANIMOUS INTEGRATED

pathophysiologyepidemiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	aflatoxin exposure and HBsAg positivity can interact multiplicatively, producing much higher HCC risk than either factor alone Falcon states HBV and aflatoxin interact multiplicatively (citing a joint RR of 59.4), matching the synergy claim. DOI:10.3390/toxins18020090, DOI:10.3390/jox15040096
openscientist	CONCORDANT	92%	The interaction between chronic HBV infection and AFB1 exposure produces a more-than-multiplicative increase in HCC risk, representing one of the best-characterized gene–environment synergies in cancer epidemiology. OpenScientist affirms the more-than-multiplicative HBV-AFB1 interaction as a canonical gene-environment synergy. PMID:19345001

Beyond loss of tumor-suppressor function, TP53 R249S confers a gain-of-function oncogenic activity operating through a CDK4-PIN1-p53R249S-c-Myc axis that drives ribosomal biogenesis and proliferation.

SINGLE INTEGRATED

gene_functionpathophysiology

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	90%	This CDK4-PIN1-p53R249S-c-Myc axis drives ribosomal biogenesis and cell proliferation, representing a therapeutically targetable pathway. OpenScientist details the R249S gain-of-function CDK4-PIN1-c-Myc proliferative axis and frames it as therapeutically targetable. PMID:29225033
falcon	SILENT	—	Falcon describes R249S as a tumor-suppressor lesion and covers HBx-mediated p53 disruption, but does not address the CDK4-PIN1-c-Myc gain-of-function pathway.

Host phase-II detoxification and DNA-repair polymorphisms — notably GSTM1-null, GSTT1-null, and XRCC1 variants — modify individual susceptibility to aflatoxin-related HCC.

SINGLE INTEGRATED

genetic_factor

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	90%	A meta-analysis of 33 studies confirmed GSTM1-null (OR = 1.31, 95% CI 1.07–1.61) and GSTT1-null (OR = 1.47, 95% CI 1.25–1.74) as HCC risk factors OpenScientist quantifies host GST-null and XRCC1 susceptibility genotypes, including a triple-risk combination reaching ~15-fold risk. PMID:24399650, PMID:15734960
falcon	SILENT	—	Falcon's gene-environment discussion centers on HBV viral variation (HBx, basal core promoter mutations) and does not cover host GST/XRCC1 detoxification/repair polymorphisms.

Chemoprevention with oltipraz and chlorophyllin was validated in randomized trials in Qidong, China, reducing aflatoxin biomarker burden and establishing proof-of-principle for pharmacological interception.

UNANIMOUS INTEGRATED

treatment

Provider	Stance	Score	Evidence
falcon	CONCORDANT	85%	chemopreventive interception (e.g., oltipraz, chlorophyllin, broccoli sprout beverages) was associated with major biomarker declines and marked reduction in HCC burden in Qidong Falcon reports the same Qidong chemopreventive interception agents and their biomarker/burden reductions. DOI:10.3390/toxins18020061
openscientist	CONCORDANT	92%	Randomized clinical trials conducted in Qidong, China—a high-risk area for both HBV and AFB1 exposure—established proof-of-principle for pharmaceutical chemoprevention of aflatoxin-related HCC. OpenScientist reports the Qidong randomized chemoprevention trials of oltipraz and chlorophyllin as proof-of-principle. PMID:15508099

AFB1 fosters an immunosuppressive tumor microenvironment (IL-6/NF-kB-driven M2-macrophage polarization suppressing CD8+ T cells), which is therapeutically actionable by combining anti-IL-6 with anti-PD-1.

MAJORITY LEAD

pathophysiologytreatment

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	90%	We found that AFB1 indirectly influences M2-like macrophage polarization by upregulating IL-6 expression in tumor cells through the NF-κB signaling pathway OpenScientist describes the AFB1 IL-6/NF-κB → M2 macrophage immunosuppression axis and the anti-IL-6 plus anti-PD-1 combination. PMID:40789982
falcon	PARTIAL	40%	Dual-exposure HBV(+)/AFB1(+) tumors are described as molecularly distinct with features including higher PD-L1 expression and microvessel density (review-level evidence). Falcon notes a distinct immune microenvironment (higher PD-L1, microvessel density) in dual-exposure tumors but does not describe the IL-6/NF-kB/M2 mechanism or the anti-IL-6+anti-PD-1 strategy.

Aflatoxin exposure accounts for a substantial, quantifiable share of the global HCC burden, concentrated in sub-Saharan Africa, Southeast Asia, and China.

UNANIMOUS INTEGRATED

epidemiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	85%	A systematic review/meta-analysis estimated the population attributable risk (PAR) of aflatoxin-related HCC at 17% overall (14–19%). Falcon frames the burden as a population attributable risk of 17% (14-19%), higher in HBV-positive populations. DOI:10.1016/j.ejca.2012.02.009
openscientist	CONCORDANT	85%	Of the 550,000-600,000 new HCC cases worldwide each year, about 25,200-155,000 may be attributable to aflatoxin exposure. Most cases occur in sub-Saharan Africa, Southeast Asia, and China where populations suffer from both high HBV prevalence and largely uncontrolled aflatoxin exposure in food OpenScientist gives the burden as absolute annual case counts and the same endemic geography — a complementary framing to Falcon's PAR estimate. PMID:20172840

Circulating TP53 R249S-mutated cell-free DNA is a molecular exposure and early-detection biomarker, detectable in plasma/serum before overt cancer and in asymptomatic HBV carriers.

UNANIMOUS INTEGRATED

diagnosis

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	Circulating TP53 R249S-mutated cfDNA can be detected in plasma/serum before overt cancer and in asymptomatic HBV carriers, supporting early molecular detection in endemic regions. Falcon describes circulating R249S cfDNA as an early-detection signal (with Thailand and Gambia quantitative data). DOI:10.1371/journal.pone.0037707, DOI:10.1158/1055-9965.epi-05-0612
openscientist	CONCORDANT	80%	TP53 R249S (ddPCR) \| Molecular diagnosis + exposure \| Liquid biopsy in cell-free DNA OpenScientist lists ddPCR-based TP53 R249S liquid biopsy in cell-free DNA as a molecular diagnostic and exposure biomarker. PMID:29749584

Narrative

Overview

Both providers frame aflatoxin-related HCC as a paradigm of gene-environment carcinogenesis: chronic dietary AFB1 exposure is hepatically bioactivated to a reactive epoxide that forms DNA adducts and imprints the characteristic TP53 R249S "fingerprint" mutation, with chronic HBV infection acting as a supra-multiplicative co-factor and with exposure reduction/chemoprevention as demonstrably effective public-health levers. Falcon is a biomarker- and prevention-centric report anchored on recent (2024-2026) reviews and drug-free of clinical-management detail; OpenScientist is a broader, mechanism-to-therapy report that adds molecular gain-of-function, host genetics, immune microenvironment, and standard-of-care treatment coverage.

Agreement

The two reports concur on the core causal chain — CYP-mediated AFB1 bioactivation to the 8,9-exo-epoxide, N7-guanine/FAPY adduct formation, G->T transversions, and the TP53 codon 249 R249S hallmark mutation as a molecular fingerprint and circulating early-detection biomarker. They agree on the more-than-multiplicative HBV-AFB1 synergy, on the substantial attributable global burden concentrated in sub-Saharan Africa, Southeast Asia, and China, and on validated chemoprevention (oltipraz, chlorophyllin) from the Qidong trials.

Divergence

OpenScientist uniquely develops the R249S gain-of-function CDK4-PIN1-c-Myc proliferative axis, the host phase-II detoxification/DNA-repair susceptibility genotypes (GSTM1-null, GSTT1-null, XRCC1), the AFB1-driven IL-6/NF-kB/M2 immunosuppressive microenvironment with an anti-IL-6 plus anti-PD-1 strategy, and standard HCC systemic therapy (atezolizumab plus bevacizumab). Falcon is largely silent on these, explicitly noting that clinical presentation, imaging, standard-of-care therapy, and host genetics were outside its retrieved corpus; it touches the immune axis only weakly, noting higher PD-L1 and microvessel density in dual-exposure tumors. The divergences are coverage/emphasis, not conflict — no genuine contradiction was found, and burden is expressed in complementary framings (Falcon population attributable risk of 17% vs OpenScientist absolute case counts).

Integration

Promote the shared causal-chain findings into kb/disorders/Aflatoxin_Related_HCC.yaml: AFB1 CYP bioactivation and epoxide/adduct formation, the TP53 R249S hallmark mutation (with its circulating cfDNA diagnostic role), the more-than- multiplicative HBV-AFB1 synergy, the substantial attributable epidemiologic burden, host GST/XRCC1 susceptibility genetics, the R249S CDK4-PIN1-c-Myc gain-of-function pathway, and Qidong-validated chemoprevention.

Not integrated (leads)

The AFB1-driven immunosuppressive microenvironment and the anti-IL-6 plus anti-PD-1 combination are retained as a research lead: they rest on very recent (2025-2026) preclinical work not yet validated in human trials, and Falcon corroborates only the weaker dual-exposure immune-phenotype observation. Generic HCC standard-of-care systemic therapy (not aflatoxin-specific) is likewise held as context rather than promoted as an etiology-specific mechanism.

Two independent provider reports were compared: falcon (Edison Scientific Literature; biomarker/prevention-focused) and openscientist (openscientist-autonomous; comprehensive mechanism-to-therapy). MONDO:0007256 (hepatocellular carcinoma) is taken from kb/disorders/Aflatoxin_Related_HCC.yaml; neither aflatoxin-related HCC nor a distinct etiological subtype has its own MONDO entry. No direct contradictions were identified; divergence is coverage/emphasis (OpenScientist adds gain-of-function, host genetics, immune microenvironment, and treatment) plus complementary burden framings. best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets were intentionally left to the main curation pipeline pending fetch-reference verification.